Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Migraines and cluster headaches
Anaphylactic shock
Acute adrenal crisis
Epileptic seizure
Opioid overdose
Rheumatoid arthritis
Severe asthma crisis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Available position and applications
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
Financial releases
Financial releases
Release date
Min
Max
Year
All
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Apply
2019/02/28
SUCCESS OF THE €4 MILLION CAPITAL INCREASE
Read the release
2018/12/18
Business update November 2018
Read the release
2018/10/09
First-half 2018 results and business update
Read the release
2018/10/09
Strengthening of pharma skills within the Crossject supervisory board
Read the release
2018/07/23
Crossject announces the principle of the free issue and allotment of warrants to the shareholders and new € 2.5 million convertible bond
Read the release
2018/06/04
Business update may 2018
Read the release
2018/03/20
Annual 2017 results and business update
Read the release
2018/03/01
Financial calendar 2018
Read the release
2018/02/12
Free allotment of warrants to the shareholders and issue of a convertible bond
Read the release
2018/02/01
FDA grants orphan-drug designation to ZENEO® Midazolam
Read the release
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Page
2
Page
3
Page
4
Current page
5
Page
6
Page
7
Next page
Next ›
Last page
Last »
